Cubist Systematic Strategies LLC Makes New $62,000 Investment in Zura Bio Limited (NASDAQ:ZURA)

Cubist Systematic Strategies LLC purchased a new position in shares of Zura Bio Limited (NASDAQ:ZURA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 24,675 shares of the company’s stock, valued at approximately $62,000.

Several other hedge funds also recently bought and sold shares of ZURA. American Century Companies Inc. acquired a new position in Zura Bio in the fourth quarter valued at $27,000. Prudential Financial Inc. acquired a new position in Zura Bio in the fourth quarter valued at $28,000. XTX Topco Ltd acquired a new position in Zura Bio in the fourth quarter valued at $44,000. SG Americas Securities LLC increased its stake in Zura Bio by 51.6% in the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock valued at $58,000 after purchasing an additional 7,828 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Zura Bio by 68.6% in the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock valued at $58,000 after purchasing an additional 9,379 shares during the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Trading Down 2.7%

ZURA stock opened at $1.08 on Tuesday. Zura Bio Limited has a 12-month low of $0.97 and a 12-month high of $6.31. The stock has a 50-day moving average price of $1.27 and a two-hundred day moving average price of $1.93. The company has a market cap of $73.85 million, a PE ratio of -1.54 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Equities analysts forecast that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on ZURA. HC Wainwright reiterated a “buy” rating on shares of Zura Bio in a research note on Thursday, April 3rd. Guggenheim reiterated a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a research note on Wednesday, March 26th. Oppenheimer lowered their price target on Zura Bio from $19.00 to $17.00 and set an “outperform” rating for the company in a research report on Friday, May 9th. Finally, Chardan Capital lowered their price target on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Zura Bio presently has an average rating of “Buy” and an average price target of $14.33.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.